Nausea (common), flushing, headache, and a transient rise in blood pressure.
Nausea usually eases; if blood pressure is a concern, do not redose.
Chest pain, a severe headache, or fainting → 911.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A metabolite-derived analog of melanotan II, refined for MC4R preference and stripped of the C-terminal amide. It acts centrally rather than vascularly — unlike PDE5 inhibitors, which act on peripheral blood flow, bremelanotide modulates MC4R signalling in hypothalamic pathways governing sexual desire.
Completed a full development programme. The RECONNECT phase 3 trials supported approval for hypoactive sexual desire disorder in premenopausal women. An earlier intranasal formulation was abandoned after blood-pressure signals; the subcutaneous route was carried forward.
FDA-approved as Vyleesi for acquired, generalised hypoactive sexual desire disorder in premenopausal women. Prescription-only. Approval is narrow — it does not extend to men or to general sexual-performance use.
Nausea is common and frequently treatment-limiting. Transient blood-pressure increase and heart-rate decrease; contraindicated in uncontrolled hypertension or known cardiovascular disease. Focal hyperpigmentation with repeated use.
Vyleesi: 1.75 mg SC as needed, at least 45 minutes before activity; maximum one dose per 24 hours and eight per month. FDA-label.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.